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Respiratory syncytial virus (RSV) is responsible for severe low respiratory tract infections in young infants and the elderly.
To investigate whether BBG2Na, a recombinant subunit vaccine comprising aa 130–230 of the RSV G protein, induced
protective Abs in subjects over 60 years during phase II clinical trial, pre- and postimmunization sera of individuals
immunized with BBG2Na or placebo were transferred into SCID mice before RSV challenge. These sera dose-dependently
reduced lung RSV titers. However at some points of serial dilutions, postimmunization sera of BBG2Na-immunized subjects
only were significantly more efficient than the corresponding preimmunization sera, in agreement with the induction of an
increased Ab response against multiple epitopes on RSV-A G protein. Thus, BBG2Na is immunogenic in the elderly and
confers passive protection in mice after serum transfer. To our knowledge, this is the first description of protective AbsINTRODUCTION
Respiratory syncytial virus (RSV) is a pneumovirus
encountered worldwide. This virus is the single most
important cause of serious lower respiratory tract dis-
ease in infancy and early childhood, responsible for
bronchiolitis, hospitalizations, and more than 2500 deaths
in 1997 in the United States (Shay et al., 1999, 2000). It
also represents a major risk factor for the incidence of
asthma and sensitization to common allergens (Sigurs et
al., 1995). Despite the induction of cellular and Ab re-
sponses, a protective immunity is not achieved after the
first encounter of the virus and reinfections are frequent
throughout life (Hall et al., 1991; Henderson et al., 1979).
This virus is actually recognized as a determinant
factor for pneumonia and exacerbation of chronic pulmo-
nary or cardiac diseases in adults (Dowell et al., 1996;
Sommerville, 1963). In addition, adults of advanced age
may be at particular risk for RSV-related illness. In the
United States, approximately 15–60,000 hospitalizations
and 2–7000 deaths due to RSV-associated pneumonia
occur annually among the elderly (Han et al., 1999). The
cost of RSV-related hospitalizations in this population is
estimated between $150 and $680 million per year. Thus,
the use of an RSV vaccine in the elderly and subjects
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130with underlying conditions would be largely cost-effec-
tive (Gessner, 2000).
To date, no RSV vaccine is available. We described a
new approach to develop such a vaccine (Power et al.,
1997). An RSV-A (Long strain) G protein-derived fragment
(BBG2Na) was expressed as a part of a fusion protein in
Escherichia coli (Murby et al., 1995). This recombinant
molecule appeared to be a promising vaccine candidate
for several reasons. It contains a carrier protein, BB
(Libon et al., 1999), fused to residues 130–230 of RSV G
protein (G2Na), that includes a stretch of residues (164–
173) that are completely conserved in all known RSV
isolates (Collins et al., 1996). BBG2Na is highly immuno-
genic in rodents and induces sterilizing lung protection
against both RSV-A and RSV-B infections (Power et al.,
1997). Immunopathologic responses, such as those ob-
served in the 1960s during clinical evaluation of a forma-
lin-inactivated whole RSV preparation (FI-RSV), were
never observed in murine priming models of enhanced
pathology (Corvaı¨a et al., 1997; Plotnicky-Gilquin et al.,
1999a). In addition, BBG2Na remained highly immuno-
genic in newborn mice despite the presence of RSV-
specific maternally-acquired Abs (Siegrist et al., 1999), as
well as in RSV-primed mice (Goetsch et al., 2000).
The safety and the efficacy of BBG2Na in different
animal models, including primates (Trudel et al., 1998),
prompted the molecule to clinical studies. Phases I andinduced by a subunit vaccine in human. © 2002 Elsevier Scien
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II were carried out (Power et al., 2001; LeCam et al., 2000)
and a Phase III in the elderly population is currentlyce (USA
passiv
going on. Adjuphos-precipitated BBG2Na was well toler-
ated and immunogenic both in young adults (Power et
al., 2001) and in subjects aged over 60 years (LeCam et
al., 2000). Anti-G2Na-specific Ab responses were multi-
plied by a twofold factor or more in up to 68% of the
subjects. The twofold seroconversion rate against RSV-A
after 1 injection of 100 or 200 g of BBG2Na was up to
22% of the subjects.
The aim of our present study was to test whether
BBG2Na administration in the elderly during the Phase II
clinical trial induced anti-RSV-A protective Abs. For this
purpose, the protective efficacy of pre- and postimmuni-
zation sera of 11 subjects immunized with BBG2Na or
with placebo were evaluated by transfer at serial dilu-
tions into SCID mice before challenge with RSV-A. The
Ab profiles were also determined by pepscan analysis.
RESULTS
Characterization of the antibody responses
Three hundred eight subjects, aged 60–80 years, were
enrolled in the clinical trial and assigned to vaccine or
placebo groups in a randomized, double-blind, and con-
trolled fashion (LeCam et al., 2000). Eleven of them were
selected on the basis of the Ab responses detected in
the sera before the first immunization and 28 days there-
after. The selected subjects were injected once with 100
or 200 g of BBG2Na or the placebo. The prevaccination
anti-G2Na IgG titers were quite similar except for the
subject PER; they comprised between 67 and 137 arbi-
trary units (AU) ml (mean of SEL serum titers: 91  19
AU/ml) (Table 1). Four weeks after the first immunization,
the subjects who received BBG2Na showed a 7- to
37-fold increase in their anti-BBG2Na Ab titers (mean of
V serum titers: 7258  3458 AU/ml versus mean of SEL
serum titers: 521  318 AU/ml). This increase was attrib-
utable to the induction of IgG to BB, the carrier protein,
and G2Na. For all subjects, anti-G2Na IgG titers were
multiplied at least by a fourfold factor. Similarly, BBG2Na-
immunized subjects also showed an increase in their
serum of anti-RSV-A IgG titers, although the magnitude of
this increase did not necessarily correlate with that ob-
served for the anti-G2Na IgG titers. RSV-A neutralization
titers remained relatively stable except for individual
POI and PER for whom the VN titers increased more
than six and five times, respectively. This increase was
not due to an RSV infection, since Ab titers to RSV F
protein were not modified (data not shown). In addition,
a slight increase was induced following BBG2Na immu-
nization in the anti-RSV-B IgG response of individuals
POI and ADE.
Reactivities of sera with synthetic peptides
To analyze the IgG responses and determine epitope
usage before and after immunization with BBG2Na in the
TABLE 1
Serologic Responses of BBG2Na- and Placebo-Immunized Subjects













BBG2Na (100 g) POI SEL 91 298 961 565 361 162
V 571 4602 7438 3736 671 1089
PER SEL 322 16 322 1255 222 68
V 1333 4195 6416 4666 361 382
BBG2Na (200 g) LIA SEL 85 145 811 702 256 261
V 743 5147 13054 1761 233 310
CAL SEL 100 31 165 430 181 229
V 1949 3628 6216 847 200 272
GAU SEL 67 182 280 1107 443 297
V 982 1635 2383 1633 448 707
ADE SEL 81 122 589 1552 512 126
V 646 2795 8041 3092 834 261
Placebo BUR SEL 99 106 253 1280 892 458
V 66 77 216 1370 671 324
LAI SEL 86 56 190 335 197 544
V1 43 27 168 206 138 1089
ROY SEL 92 250 242 2647 643 877
V 80 70 159 3404 566 585
VAC SEL 137 80 354 1196 421 521
V 108 75 259 1238 316 620
BIE SEL 74 401 2099 124 84 80
V 47 255 1418 75 51 135
a SEL, preimmunization sera; V, sera harvested 4 weeks after the first immunization.
b Serum IgG and VN titers are expressed in AU/ml calculated as indicated under Materials and Methods.
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selected subjects, SEL and V sera were screened in
pepscan using a series of overlapping dodecapeptides
that spanned G2Na. Results of two representative sub-
jects, one placebo and one immunized, sharing similar
anti-G2Na Ab profiles before immunization, are shown in
Figs. 1A–1D. BIE received the placebo, while GAU was
immunized with BBG2Na. SEL sera of the two patients
shared several zone reactivities (Figs. 1A and 1C): the
major ones were located between aa 158 and 169 or 160
and 171, while minor reactivities were also observed with
12-mer peptides spanning aa sequences 141 to 159, 177
to 198, 204 to 215, 209 to 220, and 213 to 224.
The reactivities observed after immunization with pla-
cebo were comparable with those observed before im-
munization, with the exception of a new peak on peptide
163–174 (Fig. 1B). The common reactivities were all de-
tected at comparable intensity before and after immuni-
zation, consistent with the similarity in the anti-G2Na Abs
titers measured in SEL and V sera of this subject (Table
1). In contrast, although the major zone reactivities were
also conserved between SEL and V sera of the BBG2Na-
immunized subject, after immunization, these zones
were detected at a higher intensity, and enriched with
several additional peaks: peptides 130–141, 137–148,
139–150, 161–172, 164–175, 173–184, 176–187, and 180–
191 (Fig. 1D). However, these peaks were not specific for
BBG2Na, as they were also observed in some preimmu-
nization sera (not shown), indicating that they could be
induced after repeated natural RSV infections. Some of
these reactivities (underlined in Fig. 1D) coincided with
previously described protective epitopes in mice (Plot-
nicky-Gilquin et al., 1999). Thus, immunization with
BBG2Na boosted the anti-RSV Ab responses against
multiple epitopes located on the G protein.
Protective efficacy of SEL and V sera after transfer
into SCID mice
To compare the protective efficacy of pre- and postim-
munization sera of BBG2Na- and placebo-injected indi-
viduals, we set up a passive transfer model in SCID
mice. To do so, we initially used sera of young adult
FIG. 1. The reactivities of pre- (SEL) and postimmunization (V) sera from individuals BIE (immunized with placebo) and GAU (immunized with
BBG2Na) against overlapping 12-mer peptides spanning the region containing residues 130–230 of RSV-A G protein were evaluated by pepscan
analysis at dilution 1/5000. Reactivity peaks are numbered to facilitate direct comparison of the various sera, the numbers corresponding to the first
amino acid residue of the implicated peptide. The level of the background values is indicated by a line. Peptides coinciding with previously described
protective epitopes in mice are underlined.
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healthy volunteers of the Phase I study. Our previous
studies demonstrated that RSV-A protection can be ac-
complished in mice, following passive Ab transfer using
either the intraperitoneal (i.p.) or the intranasal (i.n.) route
(Power et al., 1997; Plotnicky-Gilquin et al., 1999b). Ac-
cordingly, i.p. and i.n. transfer of serially diluted sera from
Phase I trial into SCID mice resulted in reduction of lung
RSV-A titers in a dose-dependent manner (not shown). In
both cases, a sterilizing protection could be achieved
with the undiluted human sera comparing favorably with
the control murine anti-RSV-A serum. In contrast, when
these sera were diluted 1/100, they had no more effect as
lung RSV-A titers of mice were similar to those of mice
treated with irrelevant Abs (i.e., the murine anti-BB se-
rum). However, to obtain the same level of protection, the
i.n. transfer (performed with 50 l/mouse) required sig-
nificantly less serum than the i.p. transfer (performed
with 200 l/mouse). Hence, we chose to test the sera of
the 11 selected individuals of Phase II using the i.n. route.
As shown in Fig. 2A, although the maximum level of
lung infection (given by the group of mice treated with the
anti-BB serum) varied with the experiment (from 3.8 0.3
to 5.2 log10 TCID50/g lung), all SEL and V sera induced a
dose-dependent reduction of lung RSV-A titers after i.n.
instillation into SCID mice. In addition, at a dilution of
1/10, the efficacy of SEL sera varied considerably with
the subjects. However, the postimmunization sera of all
BBG2Na-immunized subjects significantly reduced lung
RSV-A titers compared with the corresponding preimmu-
nization sera, at least at one of the three dilutions tested
(P  0.05). In contrast, at either dilution, there was no
significant difference in lung RSV-A titers between mice
treated with the pre- and postimmunization sera of the
subjects vaccinated with placebo (Fig. 2B). Similar re-
sults were obtained in separate experiments, as shown
by lung RSV-A titers measured in the first and in the second
test performed with SEL and V sera of subject LAI.
To investigate the influence of the route of serum
transfer on the protection results, the protective efficacy
of the pre- and postimmunization sera of subjects GAU
and CAL (both vaccinated with BBG2Na) and BIE (im-
munized with placebo) were also evaluated after transfer
by i.p. injection. As shown in Table 2, at a dilution of 1/2,
after immunization, the sera of GAU and CAL reduced
lung RSV-A titers in mice more efficiently than the corre-
sponding preimmunization sera (P  0.05). In contrast,
lung RSV-A titers were similar in mice treated with SEL
and V sera of BIE, the placebo-immunized individual.
In conclusion, our results demonstrated that the anti-
RSV-A protective efficacy of the serum was significantly
increased in the elderly after immunization with BBG2Na,
and not with the placebo, in comparison with the sera
obtained from these subjects before immunization. This
effect was demonstrated by passive transfer of the pre-
and postimmunization sera into SCID mice, using either
the i.p. or the i.n. route.
DISCUSSION
RSV is increasingly recognized as an important patho-
gen in the elderly, with a rate of associated disease
probably close to that of influenza (Dowell et al., 1996;
Falsey et al., 1995). Immunoprophylaxis and immunother-
apy with hyperimmune globulins or with humanized
monoclonal Abs against RSV are very expensive and
their use is restricted to high-risk newborns or infants.
Antiviral therapy is controversial and of limited effective-
ness (Kahn, 2000; Zambon, 1999). Therefore, developing
an RSV vaccine for the elderly appears to be the solution
of choice to control excess morbidity and mortality due to
RSV in this population. In the present article, we demon-
strated that BBG2Na, an RSV G protein-derived recom-
binant vaccine, successfully induced protective Abs
against RSV infection in the serum of individuals aged
over 60 years, as shown in a passive immunization
mouse model.
The in vivo anti-RSV-A protective efficacy of human
sera was previously investigated in the 1980s, in a cotton
rat model (Prince et al., 1985). In this model, sera of
RSV-convalescent individuals and purified Igs were
transferred by i.p. injection into rats before RSV chal-
lenge, at the dose of 0.5 ml/10 g of body weight. This
represents at least 4 to 5 ml of serum required for the
transfer into a single animal. Since only small volumes
(generally  1 ml) of SEL and V sera of each individual
were available in our hands, we set up a transfer model
using SCID mice instead of the cotton rats. After chal-
lenge with RSV, these immunoincompetent mice develop
a chronic infection in lungs (Plotnicky-Gilquin, personal
observation). In addition, the transfer of human sera
might be facilitated by their lack of Abs. Passive immu-
nizations were performed either by the i.p. or by the i.n.
route, the latter condition allowing us to make the com-
parisons with extremely low final volumes of sera (i.e.,
50 l for the i.n. versus at least 1800 l for the i.p.
route). Under either condition, pre- and postimmunization
sera of placebo-treated individuals showed similar pro-
tective activities. In contrast, postimmunization sera of
BBG2Na-immunized subjects displayed a significantly
increased protective efficacy against RSV-A lung infec-
tion, after transfer into SCID mice, compared with the
corresponding preimmune sera.
Surprisingly, no correlation could be clearly estab-
lished between the IgG responses, the neutralization
titers, and the effectiveness of the different sera. This
might be due at least in part to the relative variability
observed in the level of RSV-A infection of our mouse
model. However, it also probably reflects the complexity
of individual responses raised against the different RSV
proteins, after repeated natural infections with different
virus strains, these responses being more or less mod-
ified upon immunization with BBG2Na.
The lack of correlation also suggests that increasing
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the neutralization titer is not a prerequisite to improve the
anti-RSV protective efficacy of human sera. This hypoth-
esis is supported by the observation that several anti-
G2Na monoclonal Abs that failed to neutralize RSV in-
fection in vitro were nonetheless able to induce lung
sterilizing protection in vivo after transfer into SCID mice
FIG. 2. Pre- (SEL) and postimmunization (V) sera from BBG2Na- (A) or placebo-immunized individuals (B) were transferred intranasally into SCID
mice diluted 1/10, 1/50, or 1/100 in PBS, before RSV challenge. Control mice for infection received similarly the control anti-BB serum, as indicated
under Materials and Methods. Lung RSV-A titers were determined 5 days later. SEL and V sera from individual LAI were tested in two separate
experiments. Results represent mean RSV-A titers  SD calculated from groups of five to six mice. Comparisons were made between groups treated
with SEL or V sera used at the same dilution. *P  0.05.
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(Power et al., 1997; Plotnicky-Gilquin et al., 1999b). In
addition, we found that BBG2Na consistently displayed a
high protective efficacy in rodent models despite the
induction of low serum neutralization titers (Power et al.,
1997).
Analysis of epitope usage using a pepscan revealed
the presence in the preimmunization sera of an already
established Ab response against several epitopes on the
G protein fragment. The profile of peak reactivities
showed some variations between different subjects,
most notably in intensities. However, similar major zone
reactivities were evident in these sera, most particularly
in regions spanning amino acids 158 to 165 and 177 to
189. Importantly, the preimmunization reactivities were
detected at a higher intensity after immunization with
BBG2Na. The postimmunization sera were also enriched
with new peaks (Figs. 1C and 1D), although none of
these peaks appeared to be specifically induced by
BBG2Na, since they were also observed (though at dif-
ferent levels of intensity) in several preimmunization sera
(not shown). A number of minor reactivities also disap-
peared in some subjects due to the increase of antibody
titers and the resulting increased background values.
Nonetheless, it was worth noting that a number of the
reactivities boosted after BBG2Na immunization (such as
peptides 152–164, 164–176, 173–187, and 176–188) coin-
cided with previously identified mouse protective epitopes
(Plotnicky-Gilquin et al., 1999b).
Overall, the data suggested that, although repeated
RSV infections induce a response against a large panel
of epitopes on the G protein, IgG responses to a number
of these epitopes may progressively disappear in the
elderly, consistent with observations concerning the
modification of the B cell repertoire during aging (Wek-
sler, 2000). BBG2Na is able to boost and/or to restore in
part these antibody responses, and thus to increase the
resulting serum protective efficacy.
The mechanisms underlying anti-RSV protection in hu-
mans are not yet completely understood; they probably
involve both humoral and cellular responses. In animals,
neutralization, ADCC, and complement activation may
contribute with Abs to elimination of RSV (Meguro et al.,
1979; Corbeil et al., 1996). In addition, it is not clear if the
increased protective efficacy of postimmune sera ob-
served in SCID mice would be sufficient to increase the
protection of the elderly against RSV infection. In this
case, BBG2Na would represent an interesting vaccine to
administer in the elderly, alone or in association with an
influenza vaccine. It would considerably reduce disease
burden and limit health problems due to viral respiratory
infections in this population and might also contribute to
the control of virus spread to other individuals.
MATERIALS AND METHODS
Virus, cells, and ELISA antigens
Respiratory syncytial virus subgroup A (RSV-A) (Long
strain, ATCC VR-26, American Type Culture Collection,
Rockville, MD) propagation in HEp-2 cells (ECACC
86030501, European Collection of Animal Cell Cultures,
Porton Down, Salisbury, U.K.), as well as the production
of viral protein and uninfected cell ELISA antigens, were
performed as previously described (Power et al., 1997).
Viruses were harvested after 48–72 h by scraping at-
tached cells into the medium, centrifuging the suspen-
sion at 460 g for 15 min, and collecting the supernatant
as the virus stock. RSV was stored at 196°C until use.
Immunization procedure and sera
BBG2Na was purified (99%) from E. coli cell lysates.
The vaccine was supplied in two separate vials including
BBG2Na freeze-dried with mannitol and aluminum phos-
phate (ADJU-PHOS, Superfos, Denmark) suspended in
water. The formulation was reconstituted just before use
and injected into the deltoid muscle. Vaccinees received
one or two doses of 50, 100, or 200 g of BBG2Na
(patient surnames are noted “”), each containing 560 g
aluminum, or of placebo (saline) (patient surnames are
noted “”), at a 28-day interval. Blood samples were
harvested before the first injection (designed “SEL” sera)
and 4 weeks after the first injection (designed “V” sera).
These sera were kept at 80°C until use. The sera of
two nonimmunized adult healthy volunteers were also
used to set up the passive transfer experiments.
Immunological assays
ELISA. Serum total IgG levels were determined using
RSV-A (Long) or B (B1 wt; ATCC VR 1400) infected HEp-2
cell lysates, BBG2Na, G2Na, or BB as coating antigens at
TABLE 2




SEL undiluteda 1.48 0.04b 2.12 0.90 2.2 0
SEL 1/2 4.1 0.28 3.4 0.34 3.95 0.25
SEL 1/5 4.45 0.14 3.5 0.37 4.45 0.38
V undiluted 1.48 0.04 1.8 0.24 2.2 0.25
V 1/2 3.41 0.23*c 2.6 0.30* 3.8 0.28
V 1/5 4.33 0.19 3 0.40 4.45 0.25
anti-BB 4.6 0.20 4.05 0.30 4.85 0.14
anti-RSV-A 1.8 0.70 1.45 0 1.5 0.12
a Preimmunization (SEL) and postimmunization (V) sera were trans-
ferred pure or diluted 1/2 or 1/5 in PBS before i.p. injection of 200 l into
SCID mice. The control anti-BB and anti-RSV-A sera were transferred at
anti-BB and anti-RSV-A ELISA titers of 5 log10.
b Mean RSV-A titers  SD expressed in log10 (TCID50)/lung and
calculated from groups of five to six mice.
c P  0.05. Comparisons were made between groups treated with
SEL and V sera of the same subject, used at the same dilution.
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previously optimized protein concentration (Power et al.,
2001). Serial serum dilutions were incubated with the
coating antigens. Bound IgGs were detected with HRP-
conjugated anti-human IgG (Biosource International,
Camarillo, CA). Total IgG levels in test sera against viral
antigens were expressed as arbitrary units per ml (AU/
ml) based on standard curves generated with an internal
working standard (a pool of sera of BBG2Na-immunized
volunteers from Phase I trial) following absorbance read-
ing at OD450.
Virus neutralization (VN) assay. Virus neutralization
assay was performed as previously described (Power et
al., 2001). Briefly, serial twofold dilutions of heat-inacti-
vated (56°C  30 min) test serum were prepared in
triplicate in DMEM with 1% fetal bovine serum (FBS)
(BioWhittaker, Walkersville, MD) in 96-well flat-bottomed
plates (Greiner) (50 l/well). Approximately 100 tissue-
culture infectious dose 50 (TCID50) RSV-A or B in 50 l
were added per well and plates were incubated at 37°C
for 1 h. Following incubation, 104 and 5 103 HEp-2 cells
were added per well for RSV-A and B VN assays, respec-
tively. After 6–8 days at 37°C, cytopathic effect was
scored for each well. Fifty percent VN titers were calcu-
lated by the Reed and Muench method (1938). Two ref-
erence human sera (average VN titers 1/40) were treated
in a similar fashion and were used as the basis to
calculate arbitrary VN AU titers/ml for each test serum
sample, using the following formula: (VN titer of test
serum/average VN titer of two reference sera)  100.
Animals
Female SCID BALB/c mice, aged 7–8 weeks, were
purchased from IFFA CREDO (L’Arbresle, France) and
kept under specific pathogen-free conditions. They were
fed rat and mouse maintenance diet A04 (UAR, Villem-
oissin-sur-Orge, France) and water ad libitum and were
housed and manipulated according to French and Euro-
pean guidelines.
Protection studies
For passive transfer experiments, mice were anesthe-
tized by intramuscular (i.m.) injection of 2.5 ml/kg of a 4/1
mixture (v/v) of ketamine (Imalge`ne 500) (Rhoˆne Me´rieux,
Lyon, France) and xylazine (Rompun at 2%) (Bayer, Puteaux,
France).
Pre- and postimmunization sera were transferred pure
or diluted in PBS, by i.p. injection of 200 l, or by i.n.
instillation of 50 l per mouse, using 5–6 mice per dilu-
tion. Control mice for infection and for protection were
treated, respectively, with an anti-BB or an anti-RSV-
serum, diluted at an anti-BB or an anti-RSV-A ELISA titer
of 5 log10. These murine polyclonal antisera were pro-
duced by immunizing BALB/c mice three times at 2-week
intervals by i.p. injections of 20 g BB in 20% aluminum
phosphate or by i.n. instillation of 105 TCID50 RSV-A.
Three weeks after the last immunization, the mice were
sacrificed and exsanguinated by cardiac puncture. Blood
samples were collected in serum separation tubes
(Beckton–Dickinson, Meylan, France) and centrifuged at
1850 g for 10 min, and the sera were pooled. The titers of
the resulting anti-BB and anti-RSV-A antisera were de-
termined as previously described (Power et al., 1997).
These sera were stored at 20°C until use in passive
transfer experiments.
Eighteen hours after the serum transfer, the animals
were challenged with 105 TCID50 RSV-A i.n., as described
above. The mice were sacrificed 5 days later, after an-
esthesia and exsanguination by cardiac puncture. Lung
removal, lung homogenate preparation, and virus titra-
tion were undertaken as previously described (Power et
al., 1997). The limit of detection for lung tissues was
1.45 log10 TCID50/g of lung, except where insufficient
lung homogenate was available. When no virus was
detected, actual detection limits were used for statistical
analyses. Thus, standard deviations  0 were occasion-
ally recorded for lung titers of some virus-free animal
groups. Organs were considered protected when virus
titers were reduced by at least 2 log10 relative to anti-BB-
treated control mice.
Pepscan analysis
Ninety overlapping 12-mer peptides spanning resi-
dues 130–230 (G2Na) of the human RSV-A G protein
were synthesized on nonclivable derivatized rods (Mimo-
topes, Clayton Victoria, Australia) according to estab-
lished procedures. The peptides were tested for their
reactivities with sera by ELISA. Briefly, nonspecific bind-
ing was blocked by incubation for 1 h at 37°C with
phosphate-buffered saline (PBS) containing 0.1% Tween
(Sigma) and 1% gelatin. The rods were subsequently
incubated at 4°C overnight with the sera, washed three
times, and incubated 1 h at room temperature (RT) with a
HRP-conjugated goat anti-human antibody (1/5000)
(Southern Biotechnology Associates, Birmingham, AL).
After washing four times, the blocks of pins were placed
in a 96-well microtiter plate (Nunc, Roskilde, Denmark)
containing 100 l tetramethyl benzidine (Dynatech,
Chantilly, VA). The reaction was terminated 7 min later
with 100 l/well of 1 M H2SO4. Optical densities (OD)
were measured at 450 nm. A reactivity was analyzed as
a positive signal when the measured optical density was
higher than twice the background value; the background
value was determined as the mean of the 10 minor
optical densities measured in the plate.
Statistics
Statistical analyses were done using the t test or
Kolmogorov–Smirnov of the Statigraphic software pro-
gram (Manugistics, Rockville, MD), depending on the
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normal distribution of the values. Probability values
greater than 0.05 were considered insignificant.
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